{"id":2533,"date":"2025-08-18T09:00:00","date_gmt":"2025-08-18T13:00:00","guid":{"rendered":"https:\/\/glycovax.com\/?p=2533"},"modified":"2025-10-07T10:26:21","modified_gmt":"2025-10-07T14:26:21","slug":"glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa","status":"publish","type":"post","link":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/","title":{"rendered":"Glycovax Pharma obtient une licence du Conseil national de recherches du Canada pour d\u00e9velopper un vaccin contre les maladies nosocomiales li\u00e9es aux infections \u00e0 Pseudomonas aeruginosa (Pa)"},"content":{"rendered":"\n

Montr\u00e9al, Canada, 18 ao\u00fbt 2025<\/strong> \u2013 Pseudomonas aeruginosa<\/em> (Pa<\/em>) est une bact\u00e9rie responsable d\u2019infections nosocomiales et souvent mortelle lorsqu\u2019elle est contract\u00e9e par des personnes atteintes de fibrose kystique. Il n\u2019existe actuellement aucun vaccin pour pr\u00e9venir les infections li\u00e9es \u00e0 Pa<\/em>, m\u00eame si cette bact\u00e9rie est consid\u00e9r\u00e9e comme une cible hautement prioritaire par l\u2019Organisation mondiale de la Sant\u00e9 (OMS).<\/p>\n\n\n\n

L\u2019\u00e9quipe du Conseil national de recherches du Canada (CNRC) a identifi\u00e9 un antig\u00e8ne cible pr\u00e9sent dans la capsule de saccharides de plusieurs souches de Pa<\/em>, qui est immunog\u00e8ne, s\u00fbr et qui a d\u00e9montr\u00e9 une activit\u00e9 bact\u00e9ricide prometteuse lors d\u2019essais pr\u00e9liminaires in vivo<\/em> lorsqu\u2019il \u00e9tait incorpor\u00e9 dans un vaccin conjugu\u00e9. Glycovax a obtenu du CNRC une licence pour poursuivre le d\u00e9veloppement de cet antig\u00e8ne glycannique prometteur sous forme de vaccin glycoconjugu\u00e9 semi-synth\u00e9tique afin de lutter contre les infections \u00e0 Pa<\/em>.<\/p>\n\n\n\n

Contexte<\/em><\/strong> \u2013 L\u2019utilisation g\u00e9n\u00e9ralis\u00e9e des antibiotiques depuis les ann\u00e9es 1950 constitue l\u2019un des progr\u00e8s th\u00e9rapeutiques les plus importants du XXe<\/sup> si\u00e8cle, ayant contribu\u00e9 \u00e0 augmenter l\u2019esp\u00e9rance de vie plus que tout autre traitement m\u00e9dical. Toutefois, cette approche a entra\u00een\u00e9 l\u2019apparition d\u2019une r\u00e9sistance aux antibiotiques (RA) chez certains micro-organismes et une diminution de l\u2019efficacit\u00e9 des traitements standards. La RA rend les infections plus difficiles \u00e0 traiter et augmente le risque de propagation des maladies dans les h\u00f4pitaux et au sein de la population g\u00e9n\u00e9rale.<\/p>\n\n\n\n

Reconnue pour ses niveaux \u00e9lev\u00e9s de RA, la Pa<\/em> est responsable de nombreuses maladies respiratoires chroniques et \u00e9volutives. Elle repr\u00e9sente la principale cause de pneumonie nosocomiale et d\u2019insuffisance respiratoire dans les h\u00f4pitaux, en particulier chez les patients atteints de fibrose kystique.<\/p>\n\n\n\n

\u00c0 propos de Glycovax Pharma inc.<\/h3>\n\n\n\n

Fond\u00e9e \u00e0 Montr\u00e9al, au Canada, en 2016, Glycovax Pharma est une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la conception et le d\u00e9veloppement de vaccins glycoconjugu\u00e9s. Gr\u00e2ce \u00e0 son expertise unique en glyco-immunologie, Glycovax Pharma se positionne \u00e0 l\u2019avant-garde de solutions vaccinales plus efficaces, particuli\u00e8rement dans les domaines des infections virales ou bact\u00e9riennes et du cancer. Pour plus d\u2019information, visitez : www.glycovax.com<\/a><\/p>\n\n\n\n

Pour information :<\/p>\n\n\n\n

Daniel Granger
daniel.granger@acjcommunication.com<\/a>
514\u00a0840 7990<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Montr\u00e9al, Canada, 18 ao\u00fbt 2025 \u2013 Pseudomonas aeruginosa (Pa) est une bact\u00e9rie responsable d\u2019infections nosocomiales et souvent mortelle lorsqu\u2019elle est contract\u00e9e par des personnes atteintes de fibrose kystique. Il n\u2019existe actuellement aucun vaccin pour pr\u00e9venir les infections li\u00e9es \u00e0 Pa, m\u00eame si cette bact\u00e9rie est consid\u00e9r\u00e9e comme une cible hautement prioritaire par l\u2019Organisation mondiale de…<\/p>\n","protected":false},"author":2,"featured_media":2543,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[96],"tags":[],"class_list":["post-2533","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse"],"acf":[],"yoast_head":"\nCommuniqu\u00e9 | Glycovax d\u00e9veloppe un vaccin contre Pseudomonas aeruginosa<\/title>\n<meta name=\"description\" content=\"Glycovax obtient une licence du CNRC pour un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, bact\u00e9rie cibl\u00e9e par l\u2019OMS.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 | Glycovax d\u00e9veloppe un vaccin contre Pseudomonas aeruginosa\" \/>\n<meta property=\"og:description\" content=\"Glycovax obtient une licence du CNRC pour un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, bact\u00e9rie cibl\u00e9e par l\u2019OMS.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/\" \/>\n<meta property=\"og:site_name\" content=\"Glycovax Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-07T14:26:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Claude Dagenais\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Claude Dagenais\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/\"},\"author\":{\"name\":\"Claude Dagenais\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\"},\"headline\":\"Glycovax Pharma obtient une licence du Conseil national de recherches du Canada pour d\u00e9velopper un vaccin contre les maladies nosocomiales li\u00e9es aux infections \u00e0 Pseudomonas aeruginosa (Pa)\",\"datePublished\":\"2025-08-18T13:00:00+00:00\",\"dateModified\":\"2025-10-07T14:26:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/\"},\"wordCount\":412,\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/glycovax-7i9a7324-visuel-FR-scaled.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/\",\"name\":\"Communiqu\u00e9 | Glycovax d\u00e9veloppe un vaccin contre Pseudomonas aeruginosa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/glycovax-7i9a7324-visuel-FR-scaled.jpg\",\"datePublished\":\"2025-08-18T13:00:00+00:00\",\"dateModified\":\"2025-10-07T14:26:21+00:00\",\"description\":\"Glycovax obtient une licence du CNRC pour un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, bact\u00e9rie cibl\u00e9e par l\u2019OMS.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/glycovax-7i9a7324-visuel-FR-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/glycovax-7i9a7324-visuel-FR-scaled.jpg\",\"width\":2048,\"height\":1152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glycovax Pharma obtient une licence du Conseil national de recherches du Canada pour d\u00e9velopper un vaccin contre les maladies nosocomiales li\u00e9es aux infections \u00e0 Pseudomonas aeruginosa (Pa)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"name\":\"Glycovax Pharma\",\"description\":\"Saving millions of lives by using the power of advanced medical nanotechnology.\",\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"alternateName\":\"Glycovax\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\",\"name\":\"Glycovax Pharma\",\"alternateName\":\"Glycovax\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"width\":1200,\"height\":1200,\"caption\":\"Glycovax Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\",\"name\":\"Claude Dagenais\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"caption\":\"Claude Dagenais\"},\"sameAs\":[\"https:\\\/\\\/twohumans.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 | Glycovax d\u00e9veloppe un vaccin contre Pseudomonas aeruginosa","description":"Glycovax obtient une licence du CNRC pour un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, bact\u00e9rie cibl\u00e9e par l\u2019OMS.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 | Glycovax d\u00e9veloppe un vaccin contre Pseudomonas aeruginosa","og_description":"Glycovax obtient une licence du CNRC pour un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, bact\u00e9rie cibl\u00e9e par l\u2019OMS.","og_url":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/","og_site_name":"Glycovax Pharma","article_published_time":"2025-08-18T13:00:00+00:00","article_modified_time":"2025-10-07T14:26:21+00:00","og_image":[{"width":2048,"height":1152,"url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","type":"image\/jpeg"}],"author":"Claude Dagenais","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Claude Dagenais","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#article","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/"},"author":{"name":"Claude Dagenais","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883"},"headline":"Glycovax Pharma obtient une licence du Conseil national de recherches du Canada pour d\u00e9velopper un vaccin contre les maladies nosocomiales li\u00e9es aux infections \u00e0 Pseudomonas aeruginosa (Pa)","datePublished":"2025-08-18T13:00:00+00:00","dateModified":"2025-10-07T14:26:21+00:00","mainEntityOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/"},"wordCount":412,"publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"image":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#primaryimage"},"thumbnailUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/","url":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/","name":"Communiqu\u00e9 | Glycovax d\u00e9veloppe un vaccin contre Pseudomonas aeruginosa","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#primaryimage"},"image":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#primaryimage"},"thumbnailUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","datePublished":"2025-08-18T13:00:00+00:00","dateModified":"2025-10-07T14:26:21+00:00","description":"Glycovax obtient une licence du CNRC pour un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, bact\u00e9rie cibl\u00e9e par l\u2019OMS.","breadcrumb":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#primaryimage","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","width":2048,"height":1152},{"@type":"BreadcrumbList","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-conseil-national-de-recherches-du-canada-pour-developper-un-vaccin-contre-les-maladies-nosocomiales-liees-aux-infections-a-pseudomonas-aeruginosa-pa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycovax.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Glycovax Pharma obtient une licence du Conseil national de recherches du Canada pour d\u00e9velopper un vaccin contre les maladies nosocomiales li\u00e9es aux infections \u00e0 Pseudomonas aeruginosa (Pa)"}]},{"@type":"WebSite","@id":"https:\/\/glycovax.com\/fr\/#website","url":"https:\/\/glycovax.com\/fr\/","name":"Glycovax Pharma","description":"Saving millions of lives by using the power of advanced medical nanotechnology.","publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"alternateName":"Glycovax","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycovax.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/glycovax.com\/fr\/#organization","name":"Glycovax Pharma","alternateName":"Glycovax","url":"https:\/\/glycovax.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","width":1200,"height":1200,"caption":"Glycovax Pharma"},"image":{"@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883","name":"Claude Dagenais","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","caption":"Claude Dagenais"},"sameAs":["https:\/\/twohumans.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/comments?post=2533"}],"version-history":[{"count":5,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2533\/revisions"}],"predecessor-version":[{"id":2570,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2533\/revisions\/2570"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media\/2543"}],"wp:attachment":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media?parent=2533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/categories?post=2533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/tags?post=2533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}